Riluzole

Riluzole
Clinical data
Trade names	Rilutek, Tiglutik, Exservan, others
AHFS/Drugs.com	Monograph
MedlinePlus	a696013
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
ATC code	N07XX02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx Only;
Pharmacokinetic data
Bioavailability	60±18%
Protein binding	97%
Metabolism	Hepatic (CYP1A2)
Elimination half-life	9–15 hours
Excretion	Urine (90%)
Identifiers
	IUPAC name 6-(trifluoromethoxy)benzothiazol-2-amine;
CAS Number	1744-22-5 ;
PubChem CID	5070;
IUPHAR/BPS	2326;
DrugBank	DB00740 ;
ChemSpider	4892 ;
UNII	7LJ087RS6F;
KEGG	D00775 ;
ChEMBL	ChEMBL744 ;
CompTox Dashboard (EPA)	DTXSID3045192 ;
ECHA InfoCard	100.124.754
Chemical and physical data
Formula	C8H5F3N2OS
Molar mass	234.20 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)Oc1ccc2nc(sc2c1)N;
	InChI InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13) ; Key:FTALBRSUTCGOEG-UHFFFAOYSA-N ;
	(verify)

Riluzole is a medication used to treat amyotrophic lateral sclerosis and other motor neuron diseases. Riluzole delays the onset of ventilator-dependence or tracheostomy in some people and may increase survival by two to three months.^[2] Riluzole is available in tablet and liquid form.

^ ^a ^b ^c ^d ^e "PRODUCT INFORMATION RILUTEK® (riluzole) Tablets" (PDF). TGA eBusiness Services. sanofi-aventis australia pty ltd. January 6, 2009. Retrieved February 18, 2014.
^ Miller RG, Mitchell JD, Moore DH (March 2012). "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)". The Cochrane Database of Systematic Reviews. 2012 (3): CD001447. doi:10.1002/14651858.CD001447.pub3. PMC 7055506. PMID 22419278.